The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Generalizability of FIGARO-DKD and FIDELIO-DKD trial criteria to the US population eligible for finerenone
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
People with T2D and lower levels of albuminuria (ACR 30-299 mg/g) represent a larger proportion of people with T2D with increased CVD risk but at lower risk of CKD progression.
“This recommendation also applies to people with T2D and lower levels of albuminuria (ACR 30 -299 mg/g [3 -29.9 mg/mmol]), which represent a larger proportion of people with T2D with increased CVD risk but at lower risk of CKDprogression.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [177]
The paper reports that moderately elevated albuminuria (30–300 mg/g) is more common than severe albuminuria among US adults with T2D who meet the finerenone trial criteria; it also describes moderate albuminuria as marking early CKD. It does not establish that this group has increased CVD risk but a lower risk of CKD progression relative to another group, or estimate its proportion among all people with T2D. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Metadata
- Authors
- Chiu, N., Aggarwal, R., Bakris, G. L., Pitt, B., & Bhatt, D. L.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- University of Chicago (US)
- University of Michigan (US)
- Brigham and Women's Hospital (US)
- Venue
- Journal of the American Heart Association
- Published
- 2022-04-05
- Volume
- 11
- Issue
- 7
- Pages
- e025079-e025079
- ISSN
- 2047-9980 (ISSN-L)
- PMC
- PMC9075441
- OpenAlex
- W4220715836
- Cited by
- 15
- References
- 2
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 5
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of the American Heart Association (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FIGARO-DKD, FIDELIO-DKD, finerenone, diabetic nephropathy, inclusion and exclusion criteria, generalizability, United States population, renin-angiotensin system blockade, type 2 diabetes
- MeSH terms
- Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Naphthyridines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
